Comparing the current results to its competitors, Astrazeneca Plc reported Revenue increase in the 4 quarter 2025 by 8.63 % year on year. The sales growth was above Astrazeneca Plc's competitors' average revenue growth of 8.29 %, achieved in the same quarter.
Astrazeneca Plc Net Income in the 4 quarter 2025 grew year on year by 45.33%, faster than the Astrazeneca Plc's competitors average income growth of 12.69 %
Astrazeneca Plc's Comment on Competition and Industry Peers
CTS Corporation operates in a global competitive environment, facing both domestic and international manufacturers. Competition varies by product line, with no single competitor present across all areas. Some competitors are larger and more diversified. Customer purchasing strategies, such as reducing supplier numbers or using multiple vendors, can affect CTS Corporation's sales volumes and revenues. Customers require lower costs along with higher quality, reliability, and delivery standards, presenting both opportunities and risks, including potential loss of business to competitors. CTS Corporation focuses on competing primarily in custom engineered products for major original equipment manufacturers (OEMs) and encounters typical industry risks such as technical obsolescence.
With revenue growth of 8.63 % within Overall company, Astrazeneca Plc achieved improvement in market share, within Overall company to approximately 17.28 %. << More on AZN Market Share.
*Market share is calculated based on total revenue.
Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.
Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
Merrimack Pharmaceuticals Inc utilizes a research-driven business model, focusing on the development of targeted cancer therapies. They leverage their scientific expertise and proprietary technologies in the discovery and preclinical development of potential drugs. Additionally, Merrimack seeks collaborations and partnerships to support and advance their clinical-stage programs, ultimately aiming to improve patient outcomes in oncology.
Sources:
Astrazeneca Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Astrazeneca Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
